Amarin Corporation plc (ADR) Stock Xetra
Equities
EH3A
US0231112063
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
||
0.838 EUR | 0.00% |
Sales 2024 * | 224M 209M | Sales 2025 * | 231M 216M | Capitalization | 363M 339M |
---|---|---|---|---|---|
Net income 2024 * | -60M -56.14M | Net income 2025 * | -52M -48.66M | EV / Sales 2024 * | 0.65 x |
Net cash position 2024 * | 217M 203M | Net cash position 2025 * | 187M 175M | EV / Sales 2025 * | 0.76 x |
P/E ratio 2024 * |
-5.93
x | P/E ratio 2025 * |
-6.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.73% |
Latest transcript on Amarin Corporation plc (ADR)
Managers | Title | Age | Since |
---|---|---|---|
Patrick Holt
CEO | Chief Executive Officer | 52 | 23-07-17 |
Thomas Reilly
DFI | Director of Finance/CFO | 52 | 22-06-19 |
Compliance Officer | 55 | Nov. 14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Sterling
BRD | Director/Board Member | 45 | 23-02-27 |
Odysseas Kostas
CHM | Chairman | 49 | 23-02-27 |
Keith Horn
BRD | Director/Board Member | 66 | 23-02-27 |
1st Jan change | Capi. | |
---|---|---|
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.26% | 22.19B | |
-16.16% | 21.33B | |
-7.40% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |
- Stock Market
- Equities
- AMRN Stock
- EH3A Stock